Intelligent Bio Solutions wraps up final clinical study for FDA 510(k) submission, completing all data collection
INBS sits 35% above its 52-week low of $1.52.
Summary
Intelligent Bio Solutions completed its final clinical study for the FDA 510(k) submission, with all data collection now done. The company remains on track to submit in the second half of 2026, a major step toward entering the U.S. drug screening market.
Key Events · Product Development and Regulatory · INBS
-
Final Clinical Study Completed
The multi-site Method Comparison Study enrolled 135 participants across three U.S. sites, evaluating sensitivity, specificity, and accuracy in workplace screening environments. All clinical data collection for the FDA 510(k) program is now complete.
-
FDA Submission Timeline Intact
With data collection finished, the company moves to analysis and package assembly, targeting FDA 510(k) submission in the second half of 2026. This keeps the U.S. market entry timeline on track.
-
Regulatory Milestone De-risks Program
Completion of the final study removes a key execution risk for the 510(k) submission. The company has now addressed safety, accuracy, usability, specificity, and precision requirements across multiple studies.
-
Going Concern Backdrop
The company operates under a going concern warning and has relied on dilutive capital raises. FDA clearance would open a multi-billion-dollar U.S. market and could transform the financial outlook.
Analysis · INBS · Industrial Applications And Services
The company has completed its multi-site Method Comparison Study — the last piece of clinical data needed for its FDA 510(k) submission for the fingerprint drug screening system. With all data collection now finished, the company moves into analysis and package assembly, targeting submission in the second half of 2026. This removes a key execution risk and keeps the U.S. market entry timeline on track, a critical catalyst for a micro-cap company with a going concern warning.
At the time of this filing, INBS was trading at $2.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.